Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
Journal of Bone and Mineral Research - United States
doi 10.1002/jbmr.3848
Full Text
Open PDFAbstract
Available in full text
Date
September 11, 2019
Authors
Publisher
Wiley